Pluristem Therapeutics Interest Expense 2011-2026 | PSTI

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Pluristem Therapeutics

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009
-206 K	1.68 M	843 K	887 K	78 K	-	-2 K	-25 K	-	23 K	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
1.68 M	-206 K	410 K

Quarterly Interest Expense Pluristem Therapeutics

2026-Q3	2026-Q2	2026-Q1	2025-Q4	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
593 K	-143 K	439 K	-143 K	439 K	-	-723 K	2.06 M	-621 K	-	362 K	435 K	493 K	-	-	212 K	194 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
2.06 M	-723 K	277 K

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
FSD Pharma HUGE	9.34 K	-	5743.5 %	$ 69.7 M	Canada
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Happiness Biotech Group Limited HAPP	262 K	-	1.35 %	$ 17.8 M	China
AgeX Therapeutics AGE	51 K	-	-10.17 %	$ 12.2 K	USA
Coherus BioSciences CHRS	9 M	$ 1.69	2.74 %	$ 198 M	USA
I-Mab IMAB	722 K	-	-	$ 866 M	China
Celldex Therapeutics CLDX	927 K	$ 31.56	2.29 %	$ 2.1 B	USA
Genfit SA GNFT	4.68 M	-	2.54 %	$ 160 B	France
BioNTech SE BNTX	14.2 M	$ 93.5	1.35 %	$ 22.6 B	Germany
CRISPR Therapeutics AG CRSP	86.6 M	$ 53.73	4.15 %	$ 4.83 B	Schweiz
Athira Pharma ATHA	1.24 M	-	-	$ 269 M	USA
Compugen Ltd. CGEN	281 K	$ 2.74	3.46 %	$ 256 M	Israel
Galera Therapeutics GRTX	11.4 M	-	-32.59 %	$ 7.61 M	USA
Enlivex Therapeutics Ltd. ENLV	1.93 M	$ 0.76	11.14 %	$ 34.7 M	Israel
Esperion Therapeutics ESPR	3.49 M	$ 3.13	0.32 %	$ 651 M	USA
Eton Pharmaceuticals ETON	1.06 M	$ 32.33	3.32 %	$ 870 M	USA
Forte Biosciences FBRX	-396 K	$ 21.58	-1.64 %	$ 279 M	USA
Berkeley Lights BLI	910 K	-	-7.31 %	$ 87 M	USA
Galectin Therapeutics GALT	2.79 M	$ 2.71	-2.87 %	$ 173 M	USA
IMV IMV	2.34 K	-	-	$ 13.1 M	Canada
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
Hutchison China MediTech Limited HCM	759 K	$ 11.68	-0.6 %	$ 10 B	China
Heron Therapeutics HRTX	1.34 M	$ 0.91	3.18 %	$ 152 M	USA
Cyclacel Pharmaceuticals CYCCP	354 K	-	-4.36 %	$ 27 M	USA
Freeline Therapeutics Holdings plc FRLN	2.15 M	-	-	$ 384 M	Britain
ImmuCell Corporation ICCC	476 K	$ 10.49	-0.1 %	$ 94.7 M	USA
Gracell Biotechnologies GRCL	6.74 M	-	-	$ 3.37 B	China
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Can-Fite BioPharma Ltd. CANF	561 K	$ 3.35	-2.62 %	$ 5.51 M	Israel